CardioSeq: Impact of WGS in Individuals With CVD

Study Summary

This is a prospective, single-center, open-label study to investigate the diagnostic efficacy of the TruGenome CVD test and its impact on clinical management compared to usual care in individuals with cardiovascular disease. Diagnostic yield and changes of management (CoM) will be assessed both within the WGS group and compared to a contemporaneous, matched (2:1) usual care (UC) group sourced from EHR records.

Conditions

Cardiovascular Diseases

Interventions / Drugs

TruGenome Cardiovascular Disease test

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1500 participants

Primary Completion—

Lead SponsorIllumina, Inc.

Data Retrieved2026-04-11 02:55:28.356277+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.